Ackermann Laboratory

AddtoAny

The Ackermann Lab studies diabetes (types 1 and 2) and congenital hyperinsulinism, working with mouse models, cell lines, and primary human tissue. The lab aims to identify novel pathways regulating beta cell insulin secretion, leading to innovative therapeutic strategies for these disorders.

The lab studies beta cell function genomics in diabetes by performing single-cell functional imaging followed by single-cell RNA-sequencing on islet cells from human donors with or without type 1 or type 2 diabetes. T

The Ackermann Lab also studies epigenetic regulation of beta cell differentiation and function. Based on patients with a rare genetic disorder who exhibit beta cell dysfunction, the lab team generated mouse models in which epigenetic regulators are specifically deleted in beta cells or beta cell progenitors. The lab is currently characterizing these mice and thus far has identified a difference in beta cell glucose-stimulated insulin secretion.

In addition, the Ackermann Lab performs high-throughput sequencing analyses of islet cells to determine the molecular mechanisms of congenital hyperinsulinism and cell-autonomous effects of beta cell insulin hypersecretion. These investigations complement functional studies performed by collaborators and together identify new mechanisms regulating beta cell insulin secretion.

Current studies include in vivo mouse physiology, ex vivo human islet physiology, CRISPR-Cas9 gene editing, epigenetic modification, and single-cell functional genomics.

Leader

Amanda M. Ackermann, MD, PhD

Attending Physician
Dr. Ackermann studies diabetes (types 1 and 2) and congenital hyperinsulinism using mouse models, cell lines, and primary human tissue. She aims to identify novel pathways regulating beta cell insulin secretion, leading to innovative therapeutic strategies for these disorders. Current studies include in vivo mouse physiology, ex vivo human islet physiology, CRISPR-Cas9 gene editing, epigenetic modification, and single-cell functional genomics.